Quantum BioPharma Expands PR and Investor Relations Strategy with Two Agency Partnerships

Quantum BioPharma Ltd. (NASDAQ: QNTM) has strategically hired two agencies to bolster its public relations and investor outreach efforts. Enterprise Canada Inc. has been retained indefinitely to develop the company's media strategy, while Empire Market Ventures, LLC will focus on investor marketing and outreach for a three-month period beginning February 7, 2025.

The biopharmaceutical company is advancing several promising product lines, including unbuzzd™, a rapid alcohol detoxification beverage slated for Q1 2025 availability, rekvry™, an alcohol misuse treatment, and LUCID-21-302, a potential multiple sclerosis treatment preparing to enter Phase 2 clinical trials.

Through its subsidiary Lucid Psycheceuticals Inc., the company is particularly focused on developing LUCID-MS, a patented compound demonstrating potential to prevent and reverse myelin degradation in preclinical models. The company has also strategically positioned itself in the market through a partial ownership stake in Celly Nutrition Corp., which will commercialize the unbuzzd™ product.

The partnership with Celly Nutrition includes a lucrative royalty arrangement, with Quantum BioPharma set to receive 7% of sales until reaching $250 million in payments, after which the royalty will decrease to 3% in perpetuity. This structure provides a potential long-term revenue stream while maintaining full rights to develop similar pharmaceutical and medical products.

These strategic moves underscore Quantum BioPharma's commitment to developing innovative solutions for challenging neurodegenerative and metabolic disorders, positioning the company for potential growth in the competitive biopharmaceutical landscape.